On Twitter @mitchelzoler
© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.
Video
VIDEO: Rivaroxaban plus aspirin cut cardiovascular events in stable patients
AT THE ESC CONGRESS 2017
Related Articles
![1]()
Ticagrelor reversal agent achieves quick hemostasis: REVERSE-IT
August 28, 2017
The monoclonal antibody bentracimab, which can rapidly reverse ticagrelor, was found effective and safe in an FDA-requested interim analysis of a phase 3 trial.
DOACs best aspirin after ventricular ablation: STROKE-VT
August 28, 2017
Cerebrovascular protection was far better on DOACs after catheter ablation for VT or extrasystoles in the trial and may yet be further improved.
![1]()
Direct oral anticoagulants: Competition brought no cost relief
August 28, 2017
Medicare Part D spending since 2011 has far outpaced growth in the use of oral anticoagulants.
Reversal agents curb DOAC-related bleeding but deaths still high
August 28, 2017
The meta-analysis of more than 4,000 patients also showed thrombotic events were more frequent with andexanet than with 4PCC or idarucizumab.
